• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Israel·Healthcare·REKA.TA
Share

Rekah Pharmaceutical Industry Ltd. Stocks

ILA 1131Last Updated 16.09.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

ILA 429964.22698

ILA 1131
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Rekah Pharmaceutical Industry Ltd., established in 1941 and headquartered in Holon, Israel, specializes in the production, marketing, distribution, and sale of a broad spectrum of healthcare items across Israel. The company's offerings include both prescription and over-the-counter medicines, dermo-cosmetic products, vitamins, and nutritional supplements. Its extensive portfolio comprises approximately 280 distinct pharmaceutical drugs used in various medical sectors. These encompass steroid tablets, antibiotics (such as penicillin and cephalosporin), eye drops and ointments for allergies, infections, and dryness, baby products, and dermatological treatments.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is neutral on EV/EBITDA, underpriced on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.09.2026 20:43

Revolut Is Aiming for a Dual Listing in New York and London — Storonsky

17.09.2026 19:55

"They're playing with our lives": What is known about the mathematician who called for a slowdown in the AI race

17.09.2026 19:13

Nebius shares rose 11% following a price increase for AI chips. What might this indicate?

17.09.2026 18:41

The Nasdaq jumped more than 1% on the back of falling oil prices and bond yields

17.09.2026 18:11

Is the Rally Stalling? How a Fed Rate Hike Could Affect the Markets

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026